Altimmune completes enrollment in phase 2b impact trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (mash)

Impact trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with mash; top-line efficacy data expected in q2 2025

ALT Ratings Summary

ALT Quant Ranking